2015
Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer
Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 1529-1536. PMID: 25642591, PMCID: PMC4399282, DOI: 10.1210/jc.2014-4332.Peer-Reviewed Original ResearchConceptsRadioactive iodine therapyPapillary thyroid cancerIntermediate-risk papillary thyroid cancerAdjuvant radioactive iodine therapyIntermediate-risk PTC patientsImproved overall survivalIntermediate-risk patientsOverall survivalRisk of deathRAI therapyIodine therapyPTC patientsThyroid cancerAmerican Thyroid Association riskLong-term prognosisAmerican Joint CommissionCommon endocrine malignancyPaucity of dataTotal thyroidectomyAdult patientsMultivariate adjustmentClinical factorsAggressive variantStage T3Patient group
2012
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
Reed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genetics In Medicine 2012, 15: 203-211. PMID: 22975761, PMCID: PMC3743447, DOI: 10.1038/gim.2012.119.Peer-Reviewed Original ResearchConceptsEstrogen receptor-positive breast cancerReceptor-positive breast cancerBreast cancerHormonal therapyClinicopathologic characteristicsRisk groupsEarly-stage breast cancerIncremental cost-effectiveness ratioHigh-risk characteristicsLifetime medical costsCost-effectiveness ratioLow-risk characteristicsDecision analytic modelChemotherapy useMedical costsChemotherapyPatientsHealth systemSocietal perspectiveRecurrenceCancerMultifactorial decisionTherapySupportive evidenceTreatment